Chief Operating Officer
CT
Cyrus Therapeutics
8/10Traction
Cyrus Therapeutics develops small molecule drugs targeting previously undruggable proteins to treat chronic diseases. By utilizing advanced drug discovery techniques, the company aims to create effective therapies that address significant unmet medical needs.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$32.8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Venture MiraeassetNo round attributed
- venture.miraeasset.co.kr (opens in a new tab)investor website
Funding rounds are not available yet.
Founders
Product
Problem
Many proteins implicated in chronic diseases are considered "undruggable" due to their structural properties or lack of traditional binding sites, leaving patients with limited treatment options. This presents a significant challenge in developing effective therapies for a wide range of conditions.
Solution
Cyrus Therapeutics is developing small molecule drugs designed to target these previously undruggable proteins, opening up new avenues for treating chronic diseases. The company employs advanced drug discovery techniques to identify and develop compounds that can selectively bind to and modulate the activity of these challenging targets. By successfully drugging the undruggable, Cyrus Therapeutics aims to create novel therapies that address unmet medical needs and improve patient outcomes.
Target Audience
The primary target audience includes patients suffering from chronic diseases with limited treatment options, as well as pharmaceutical companies seeking innovative drug candidates.
Features
- Focus on developing small molecule drugs.
- Targets proteins previously considered undruggable.
- Utilizes advanced drug discovery techniques.
- Aims to create effective therapies for chronic diseases.